Glycoprotein IIb–IIIa Inhibitors for Acute Ischemic Stroke
- brain ischemia
- platelet aggregation inhibitors
- platelet glycoprotein GPIIb-IIIa complex
This is an update of a Cochrane review to assemble all the available data to evaluate the efficacy and safety of glycoprotein IIb–IIIa inhibitors in people with ischemic stroke, within 6 hours from symptoms onset.1
Glycoprotein IIb–IIIa inhibitors are potent, fast, and selective antiplatelet agents that block the final common pathway to platelet aggregation by preventing the binding of fibrinogen molecules that form bridges between adjacent platelets.
We searched the Cochrane Stroke Group trials register (last searched June 10, 2013), MEDLINE …